Saturday 17 October 2026
Export ARGX’s income statement to Excel — free account
argenex SE
ARGX Healthcare Biotechnology
argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024. In the quarter to June 2026, revenue grew 59.5%, EPS grew 88.6% and free cash flow grew 537.5%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
819.14
27.13
−3.21%
Follow ARGX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | — | 5 | — |
+8 more TTM periods Free account |
| 27.07% | 0.00% | 22.63% | 0.00% | ||
| 23.15% | 0.00% | 19.54% | 0.00% | ||
ROIC |
20.71% | 0.00% | 17.19% | 0.00% | |
Return on Tangible Assets |
26.22% | 0.00% | 22.96% | 0.00% | |
Average Days of Receivables |
132.94 | 0.00 | 142.37 | 0.00 | |
Free Cash Flow per Share |
22.12 | 0.00 | 9.60 | 0.00 | |
Free Cash Flow |
1,378.46 | — | 588.50 | — | |
Capital Expenditures |
(236.98) | — | (251.29) | — | |
| Other line items | |||||
Cash ROIC |
11.49% | — | 5.44% | — | |
Accounts Receivable Turnover |
4.10 | 0.00 | 3.94 | 0.00 | |
Accounts Payable Turnover |
0.53 | 0.00 | 0.54 | 0.00 | |
Inventory Turnover |
1.50 | 0.00 | 1.15 | 0.00 | |
Average Days of Payables |
1,053.96 | 0.00 | 1,026.16 | 0.00 | |
Days of Inventory on Hand |
258.10 | 0.00 | 383.90 | 0.00 | |
Tax Rate |
(0.02) | (0.01) | 0.01 | 0.59 | |
Research and Development Expense of Revenue |
31.00% | 31.47% | 32.11% | 35.10% | |
Selling, General and Administrative Expense of Revenue |
28.86% | 30.42% | 32.18% | 33.18% | |
Share Based Compensation of Revenue |
13.35% | 0.00% | 16.40% | 0.00% | |
Interest Coverage |
392.41 | 320.63 | 258.16 | 213.48 | |
Operating CF/Net income |
0.94 | 0.00 | 0.65 | 0.00 | |
Depreciation/Fixed assets |
1.45 | — | 1.40 | — | |
Capex/Depreciation |
(3.13) | — | (3.74) | — | |
Revenue per Share |
85.52 | 76.61 | 69.31 | 60.07 | |
Operating CF per Share |
25.92 | 0.00 | 13.70 | 0.00 | |
Capex per Share |
(3.80) | 0.00 | (4.10) | 0.00 | |
Capex to Sales |
0.04 | 0.00 | 0.06 | 0.00 |
Columns are period end dates